|  |  |  |  |
| --- | --- | --- | --- |
|  | **Included in the analysis****N=352** | **Excluded from the analysisN=24** |  |
| **Age (years)** | *n1* | *%1* | *n1* | *%1* | *p-value* |
| Median (IQR) | 39 | [32-47] | 46.5 | [37-56.5] | 0.014 |
| < 35 year | 121 | 34% | 4 | 17% | 0.061 |
| 35 - 44 year | 107 | 30% | 6 | 25% |  |
| ≥ 45 year | 124 | 35% | 14 | 58% |  |
| **Gender identity** |  |  |  |  |  |
| Male | 351 | 100% | 23 | 96% | 0.124 |
| Transgender woman | 1 | 0% | 1 | 4% |  |
| **Self-declared ethnicity** |  |  |  |  |  |
| White | 301 | 86% | 20 | 83% | 0.770 |
| Non-white  | 51 | 14% | 4 | 17% |  |
| **Residence** |  |  |  |  |  |
| Amsterdam | 215 | 61% | 15 | 63% | 0.890 |
| Other | 137 | 39% | 9 | 38% |  |
| **Highest education level** |  |  |  |  |  |
| Low and intermediate  | 82 | 23% | 8 | 33% | 0.265 |
| High | 270 | 77% | 16 | 67% |  |
| **Employment** |  |  |  |  |  |
| Employed | 277 | 80% | 13 | 54% | 0.004 |
| Unemployed | 15 | 4% | 4 | 17% |  |
| Other | 56 | 16% | 7 | 29% |  |

**Supplementary Table 1: Socio-demographic and sexual behavior characteristics at baseline of those included (n=352) and excluded (n=24) from the analysis, AMPrEP observational cohort study, August 18, 2015 to February 27, 2019, Amsterdam, the Netherlands.**

|  |  |  |  |
| --- | --- | --- | --- |
| ***TableS1 (continued)*** | **Included in the analysis****N=352** | **Excluded from the analysisN=24** |  |
| **Income** | *n1* | *%1* | *n1* | *%1* | *p-value* |
| Low (≤€1700) | 88 | 26% | 11 | 50% | 0.005 |
| Middle (€1701 to €2950) | 141 | 42% | 10 | 45% |  |
| High (>€2950) | 106 | 32% | 1 | 5% |  |
| **Current steady relationship** |  |  |  |  |  |
| No | 194 | 56% | 14 | 58% | 0.805 |
| Yes | 154 | 44% | 10 | 42% |  |
| **Living situation** |  |  |  |  |  |
| Alone | 187 | 53% | 13 | 54% | 0.954 |
| With partner | 113 | 32% | 8 | 33% |  |
| With others | 52 | 15% | 3 | 13% |  |
| **Sexual preference** |  |  |  |  |  |
| Exclusively homosexual | 279 | 79% | 17 | 71% | 0.314 |
| Not exclusively homosexual | 72 | 21% | 7 | 29% |  |
| **Number of anal sex partners (3M)2** |  |  |  |  |  |
| Median (IQR) | 12 | [6-23.5] | 14 | [4.5-33] | 0.917 |
| **CAS with casual partner (6M)3** |  |  |  |  |  |
| No | 15 | 4% | 1 | 4% | 0.728 |
| Yes | 337 | 96% | 23 | 96% |  |
| **Post-exposure prophylaxis used (6M)3** |  |  |  |  |  |
| No | 325 | 92% | 24 | 100% | 0.158 |
| Yes | 27 | 8% | 0 | 0% |  |
| **HIV-positive partner with undetectable viral load (6M)3** |  |  |  |  |  |
| No | 344 | 98% | 23 | 96% | 0.451 |
| Yes | 8 | 2% | 1 | 4% |  |

|  |  |  |  |
| --- | --- | --- | --- |
| ***TableS1 (continued)*** | **Included in the analysis****N=352** | **Excluded from the analysisN=24** |  |
| **Sexually transmitted infection (6M)3,4** | *n1* | *%1* | *n1* | *%1* | *p-value* |
| No | 217 | 62% | 24 | 100% | <0.001 |
| Yes | 135 | 38% | 0 | 0% |  |

**Abbreviations:** AMPrEP=Amsterdam PrEP Project; IQR=interquartile range; 3M=three months before baseline; 6M=six months before baseline; CAS=condomless anal sex; HIV=human immunodeficiency virus.

1. Unless otherwise stated
2. In the 3 months before baseline
3. In the 6 months before baseline
4. At least one bacterial sexually transmitted infection (i.e., syphilis, urethral or rectal chlamydia, or gonorrhoea)

Data missing in employment (n=4), income (n=19), current steady relationship (n=4), sexual preference (n=1).

**Supplement 2: Sex acts per month on PrEP within each PrEP regimen (daily or event-driven) stratified by partner type, AMPrEP observational cohort study, August 18, 2015 to February 27, 2019, Amsterdam, the Netherlands**

|  |  |  |
| --- | --- | --- |
|  | **Daily regimen** | **Event-driven regimen** |
| Months on PrEP | Steady partners | Known casual partners | Unknown casual partners | Steady partners | Known casual partners | Unknown casual partners |
|  | *n* | *n* | *n* | *n* | *n* | *n* |
| 1 | 436  | 692  | 639  | 114  | 180  | 149  |
| 2 | 441  | 643  | 664  | 68  | 205  | 148  |
| 3 | 365  | 671  | 615  | 61  | 165  | 138  |
| 4 | 331  | 594  | 570  | 69  | 111  | 95  |
| 5 | 391  | 611  | 602  | 80  | 120  | 109  |
| 6 | 351  | 609  | 582  | 65  | 115  | 119  |
| 7 | 335  | 548  | 554  | 61  | 122  | 107  |
| 8 | 342  | 543  | 547  | 62  | 106  | 107  |
| 9 | 322  | 526  | 536  | 46  | 115  | 97  |
| 10 | 290  | 509  | 507  | 40  | 98  | 95  |
| 11 | 269  | 519  | 461  | 46  | 100  | 69  |
| 12 | 302  | 525  | 445  | 47  | 124  | 81  |
| 13 | 302  | 503  | 450  | 35  | 81  | 66  |
| 14 | 252  | 518  | 463  | 53  | 117  | 85  |
| 15 | 296  | 447  | 453  | 46  | 96  | 89  |
| 16 | 246  | 483  | 451  | 56  | 88  | 63  |
| 17 | 225  | 437  | 414  | 51  | 100  | 62  |
| 18 | 246  | 457  | 416  | 54  | 98  | 62  |
| 19 | 215  | 455  | 422  | 60  | 109  | 74  |
| 20 | 224  | 413  | 364  | 58  | 100  | 67  |
| 21 | 240  | 424  | 347  | 47  | 113  | 83  |
| ***Table S2 (continued)*** | **Daily regimen** | **Event-driven regimen** |
| Months on PrEP | Steady partners | Known casual partners | Unknown casual partners | Steady partners | Known casual partners | Unknown casual partners |
|  | *n* | *n* | *n* | *n* | *n* | *n* |
| 22 | 238  | 392  | 334  | 50  | 105  | 90  |
| 23 | 257  | 389  | 365  | 47  | 129  | 66  |
| 24 | 238  | 373  | 344  | 54  | 113  | 56  |
| 25 | 262  | 406  | 329  | 51  | 79  | 55  |
| 26 | 210  | 325  | 297  | 35  | 80  | 46  |
| 27 | 203  | 340  | 319  | 60  | 93  | 72  |
| 28 | 188  | 302  | 284  | 88  | 79  | 46  |
| 29 | 175  | 304  | 287  | 73  | 82  | 42  |
| 30 | 181  | 334  | 298  | 59  | 80  | 64  |
| 31 | 217  | 296  | 298  | 62  | 60  | 68  |
| 32 | 199  | 275  | 268  | 59  | 77  | 60  |
| 33 | 203  | 269  | 246  | 82  | 71  | 52  |
| 34 | 173  | 246  | 274  | 84  | 69  | 64  |
| 35 | 182  | 256  | 248  | 61  | 70  | 68  |
| 36 | 163  | 204  | 213  | 38  | 59  | 50  |

**Abbreviations:** AMPrEP=Amsterdam PrEP Project; PrEP=pre-exposure prophylaxis.

**Supplement 3: Acknowledgements of the H-TEAM consortium**

H-TEAM Steering Committee: J.E.A.M. van Bergen6;4;5, G.J. de Bree1;2, P. Brokx8, F. Deug6, M. Heidenrijk1, M. Prins3;2, P. Reiss1;7 (chair), M. van der Valk2

H-TEAM Core Project Group: J.E.A.M. van Bergen6;4;5, G.J. de Bree1;2 (chair), P. Brokx8, U. Davidovich3, S.E. Geerlings2, E. Hoornenborg3, A. Oomen6, A. van Sighem7, W. Zuilhof6 H-TEAM

Project Management: N. Schat1

H-TEAM additional collaborators: R.C.A. Achterbergh3, M. van Agtmael24, J. Ananworanich22, D. Van de Beek17, G.E.L. van den Berk11, D. Bezemer7, A. van Bijnen6, W.L. Blok11, S. Bogers2, M. Bomers24, C.A.B. Boucher13, W. Brokking26, D. Burger20, K. Brinkman11, N. Brinkman32, M. de Bruin12, S. Bruisten3, L. Coyer3, R. van Crevel29, C.G. Daans3;34, L. Dellemann6, M. Dijkstra3, Y.T. van Duijnhoven3, A. van Eeden26, L. Elsenburg26, M.A.M. van den Elshout3, C. Ester7, E. Ersan3, P. E.V. Felipa3, P.H.J. Frissen11, T.B.H. Geijtenbeek18, M.H. Godfried2, J. van Gool3, A. Goorhuis2, M. Groot26, M.L. Groot Bruinderink3, C.A. Hankins1, A. Heijnen30;31, M.M.J Hillebregt7, A. Hogewoning3, M. Hommenga3, J.W. Hovius2, Y. Janssen32, K. de Jong3, V. Jongen3, N.A. Kootstra19, R.A. Koup21, F.P. Kroon16, T.J.W. van de Laar35;36, F. Lauw37, M. M. van Leeuwen3, K. Lettinga27, I. Linde3, D.S.E. Loomans3, J.T. van der Meer2, T. Mouhebati6, B.J. Mulder3, J. Mulder25, F.J. Nellen2, A. Nijsters6, H. Nobel2, P. Oostvogel3, E.L.M. Op de Coul5, E. Peters24, I.S. Peters3, T. van der Poll2, O. Ratmann28, C. Rokx14, M.S. van Rooijen3, M.F. Schim van der Loeff3;10, W.E.M. Schoute11, G.J. Sonder3, J. Veenstra27, A. Verbon14, F. Verdult8, J. de Vocht24, H.J. de Vries3;9;10, S. Vrouenraets27, M. van Vugt2, W.J. Wiersinga2, F.W. Wit2;7, L.R. Woittiez2, S. Zaheri7, P. Zantkuijl6, M.C. van Zelm23, A. Żakowicz33, H.M.L. Zimmermann3.

1 Department of Global Health, Amsterdam UMC – location AMC, and Amsterdam Institute for Global Health and Development, Amsterdam, the Netherlands

2 Department of Internal Medicine, Division of Infectious Diseases, Amsterdam UMC – location AMC, Amsterdam, the Netherlands

3 Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands

4 Department of General Practice, Amsterdam UMC – location AMC, University of Amsterdam, Amsterdam, the Netherlands

5 Epidemiology and Surveillance Unit, Center for Infectious Disease Control, National Institute of Public Health and the Environment, the Netherlands

6 STI AIDS Netherlands, Amsterdam, the Netherlands

7 Stichting HIV Monitoring, Amsterdam, the Netherlands

8 Dutch Association of PLHIV, Amsterdam, the Netherlands

9 Department of Dermatology, Amsterdam UMC – location AMC, University of Amsterdam, Amsterdam, the Netherlands

10 Center for Infection and Immunology, Amsterdam (CINIMA), Amsterdam UMC – location AMC, University of Amsterdam, Amsterdam, the Netherlands

11 Department of internal medicine, OLVG – location East, Amsterdam, the Netherlands

12 Aberdeen Health Psychology Group, Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, United Kingdom

13 Department of viro-science, Erasmus Medical Center Rotterdam, Rotterdam, the Netherlands

14 Department of Internal Medicine and Infectious Diseases, Erasmus Medical Center, Rotterdam, the Netherlands

16 Department of Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands

17 Center of Infection and Immunity Amsterdam (CINIMA), Department of Neurology, Amsterdam UMC – location AMC, Amsterdam, the Netherlands

18 Laboratory of Experimental Immunology, Amsterdam UMC – location AMC Amsterdam, the Netherlands

19 Laboratory for Viral Immune Pathogenesis, Amsterdam UMC – location AMC Amsterdam, the Netherlands

20 Department of Pharmacy, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands

21 Immunology Laboratory, Vaccine Research Center, NIAID, National Institutes of Health

22 US Military HIV Research Program and the Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, United States

23 Department of Virology, Erasmus Medical Center, Rotterdam, the Netherlands

24 Department of Internal Medicine, Amsterdam UMC – location VUMC, Amsterdam, the Netherlands

25 Department of Internal Medicine, Slotervaart Hospital, Amsterdam, the Netherlands

26 DC Clinics, Amsterdam, the Netherlands

27 Department of Internal Medicine, OLVG – location West , Amsterdam, the Netherlands

28 School of Public Health, Faculty of Medicine, Imperial College London, London, United Kingdom

29 Department of Internal Medicine, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands

30 Sexology Center Amsterdam, Amsterdam, the Netherlands

31 GP practice Heijnen & de Meij, Amsterdam, the Netherlands

32 Elaa – First line Amsterdam Almere, Amsterdam, the Netherlands

33 AIDS Healthcare Foundation, Amsterdam, the Netherlands

34 Center of Expertise on Gender Dysphoria, Amsterdam UMC – location VUMC, Amsterdam, the Netherlands

35 Department of Medical Microbiology, OLVG, Amsterdam, the Netherlands

36 Department of Donor Medicine Research, Laboratory of Blood-borne Infections, Sanquin Research, Amsterdam, the Netherlands

37 Department of Internal Medicine, Medical Center Jan van Goyen, Amsterdam, the Netherlands